NO1358: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (16 to 80 years old) With Partial Onset Seizures

Grants and Contracts Details

StatusFinished
Effective start/end date5/18/125/30/17

Funding

  • UCB Pharma (domestic): $19,576.00